deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02312258

A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Sponsor: Takeda

Conditions Multiple Myeloma
Interventions Ixazomib Placebo
Updated 19 times since 2017 Last updated: Aug 23, 2023 Started: Apr 9, 2015 Primary completion: Aug 12, 2019 Completion: Aug 26, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02312258, this PHASE3 trial focuses on Multiple Myeloma and remains completed. Sponsored by Takeda, it has been updated 19 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Sep 2019 · 8 months · monthly snapshot~Sep 2019 – ~Dec 2020 · 15 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Oct 2023 · 8 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2023 — Oct 2023 [monthly]

    Completed PHASE3

▶ Show 14 earlier versions

  1. Dec 2022 — Feb 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jun 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE3

  3. May 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Feb 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2019 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  10. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  11. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  12. Jun 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  13. Feb 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Takeda
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus N, Denmark , Almada, Portugal , Ancona, Italy , Ankara, Turkey (Türkiye) , Aschaffenburg, Germany , Asheville, United States , Athens, Greece , Atlanta, United States , Augsburg, Germany , Badalona, Spain and 207 more locations